Rankings
▼
Calendar
CRBU
Caribou Biosciences, Inc.
$186M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-3.1% YoY
Gross Profit
$2M
100.0% margin
Operating Income
-$43M
-1823.8% margin
Net Income
-$40M
-1699.6% margin
EPS (Diluted)
$-0.43
QoQ Revenue Growth
+13.3%
Cash Flow
Operating Cash Flow
-$37M
Free Cash Flow
-$38M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$274M
Total Liabilities
$56M
Stockholders' Equity
$217M
Cash & Equivalents
$29M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$2M
-3.1%
Gross Profit
$2M
$2M
+36.9%
Operating Income
-$43M
-$46M
+6.7%
Net Income
-$40M
-$41M
+3.0%
Revenue Segments
Reportable Segment
$2M
100%
Geographic Segments
UNITED STATES
$2M
95%
Non-US
$129,000
5%
← FY 2025
All Quarters
Q2 2025 →
CRBU Q1 2025 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena